Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 5Recruiting 4Withdrawn 2Not yet recruiting 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Prostatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Non-Small-Cell Lung 20Neoplasms 18Breast Neoplasms 18Glioblastoma 17Esophageal Squamous Cell Carcinoma 16Rectal Neoplasms 15Lung Neoplasms 15Esophageal Neoplasms 15Head and Neck Neoplasms 12Uterine Cervical Neoplasms 11Neoplasm Metastasis 10Glioma 10Nasopharyngeal Carcinoma 8Stomach Neoplasms 7Radiation Injuries 7Oropharyngeal Neoplasms 7Brain Neoplasms 7Hyperthermia 6Carcinoma, Hepatocellular 6Astrocytoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Oligodendroglioma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Radiotherapy × Clear all
NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2 Recruiting
35 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Emory University

Phase 2 Recruiting
29 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Université de Sherbrooke

Phase 2 Recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04481763 2020-07-22

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Jiangxi Provincial Cancer Hospital

Phase 1/2 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡